Aethlon Medical Croissance future

Future contrôle des critères 0/6

Les bénéfices de Aethlon Medical devraient diminuer de 4.5% par an. Le BPA devrait augmenter de 57.2% par an.

Informations clés

-4.5%

Taux de croissance des bénéfices

57.2%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.1%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aug 02

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Jul 11

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Mar 18

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Nov 09

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Dec 16

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

Nov 03

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:AEMD - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2026	N/A	-12	N/A	N/A	2
3/31/2025	N/A	-12	N/A	N/A	3
9/30/2024	N/A	-11	-9	-9	N/A
6/30/2024	N/A	-11	-9	-9	N/A
3/31/2024	N/A	-12	-10	-10	N/A
12/31/2023	1	-12	-11	-11	N/A
9/30/2023	1	-12	-10	-10	N/A
6/30/2023	1	-12	-11	-10	N/A
3/31/2023	1	-12	-11	-11	N/A
12/31/2022	0	-13	-12	-11	N/A
9/30/2022	0	-13	-12	-11	N/A
6/30/2022	0	-11	-11	-10	N/A
3/31/2022	0	-10	-10	-10	N/A
12/31/2021	0	-9	-9	-9	N/A
9/30/2021	1	-9	-9	-8	N/A
6/30/2021	1	-9	-8	-8	N/A
3/31/2021	1	-8	-7	-7	N/A
12/31/2020	1	-7	-6	-6	N/A
9/30/2020	1	-6	-5	-5	N/A
6/30/2020	1	-6	-5	-5	N/A
3/31/2020	1	-6	-5	-5	N/A
12/31/2019	1	-6	-5	-5	N/A
9/30/2019	0	-7	-5	-5	N/A
6/30/2019	0	-7	-5	-5	N/A
3/31/2019	0	-6	-4	-4	N/A
12/31/2018	0	-6	-4	-4	N/A
9/30/2018	0	-5	-4	-4	N/A
6/30/2018	0	-5	N/A	-4	N/A
3/31/2018	0	-6	N/A	-4	N/A
12/31/2017	0	-6	N/A	-4	N/A
9/30/2017	N/A	-6	N/A	-4	N/A
6/30/2017	0	-7	N/A	-4	N/A
3/31/2017	0	-7	N/A	-4	N/A
12/31/2016	1	-7	N/A	-4	N/A
9/30/2016	1	-7	N/A	-4	N/A
6/30/2016	1	-6	N/A	-4	N/A
3/31/2016	1	-5	N/A	-4	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-6	N/A
6/30/2015	1	-4	N/A	-5	N/A
3/31/2015	1	-7	N/A	-5	N/A
12/31/2014	1	-13	N/A	-4	N/A
9/30/2014	1	-14	N/A	-3	N/A
6/30/2014	1	-17	N/A	-3	N/A
3/31/2014	2	-13	N/A	-2	N/A
12/31/2013	1	-9	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AEMD devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: AEMD devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: AEMD devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de AEMD devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: AEMD ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de AEMD devrait être élevé dans 3 ans

Aethlon Medical Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 45% to US$3.85

Price target increased by 27% to US$40.10

Price target decreased by 21% to US$31.55

Price target decreased by 90% to US$4.01

Price target decreased by 12% to US$6.50

No longer forecast to breakeven

Recent updates

Price target decreased by 45% to US$3.85

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

New major risk - Share price stability

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Price target increased by 27% to US$40.10

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Price target decreased by 21% to US$31.55

Price target decreased by 90% to US$4.01

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Price target decreased by 12% to US$6.50

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

New major risk - Share price stability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Consensus revenue estimates fall by 100%

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Price target decreased to US$7.00

Consensus revenue estimates increase by 178%

Insufficient new directors

Consensus revenue estimates increase by 178%

Aethlon Medical, Inc. Announces Executive Changes

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Consensus revenue estimates fall by 68%

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to US$1.24m

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical climbs on Reddit interest

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate